Apeloa Pharmaceutical Wins 2026 Global CDMO Company of the Year Award

SHANGHAI, Sept. 17, 2026 /CourierPR/ -- Apeloa Pharmaceutical Co., Ltd., a leading contract development and manufacturing organization (CDMO) based in China, has been honored with the 2026 Global CDMO Company of the Year Award by Frost & Sullivan. The accolade, presented at the 20th Frost & Sullivan Growth, Innovation & Leadership (GIL) Global Summit, recognizes Apeloa's exceptional performance and innovation in the pharmaceutical industry.

Founded in 2006, Apeloa has grown from a traditional API manufacturer into a research-driven, end-to-end CDMO. The company's strategic evolution is evident in its fully integrated "API + Drug Product" synergy, which spans eight manufacturing sites. This comprehensive approach allows for streamlined progression from registered starting materials (RSM) and advanced intermediates to APIs and finished dosage forms.

Apeloa's technological prowess is showcased through its high-barrier tech platforms, which include flow chemistry, peptide synthesis, conjugate library service, synthetic biology & biocatalysis, high-potency compound handling, crystallization & particle engineering, oligonucleotide synthesis, and preparation & purification. These platforms enable the company to address complex synthetic challenges and provide global biotech partners with solutions for reducing risk in complex candidate development.

The company's commitment to global compliance is reflected in its pristine regulatory track record. Apeloa has successfully passed 20th US FDA inspections since 2006, and it complies with regulations from the EU EMA/EDQM, Japan PMDA, and China NMPA. This robust compliance ensures uninterrupted supply chain security for vital cardiovascular, anti-infective, CNS, and oncology pipelines.

Apeloa's global innovation network, comprising R&D centers in Boston, Shanghai, and Hengdian, is seamlessly integrated with scalable commercial-scale manufacturing backbones. This setup provides agile global support to its diverse client base, which includes multiple top-20 global pharmaceutical companies. The company generated over 44% of its revenue from overseas markets, underscoring its international reach and market performance.

In addition to the Global CDMO Company of the Year Award, Apeloa was also distinguished with five premier industry honors, including the '2026 CDMO Best Service Provider Award' at the CMC-China 2026 conference. George Cai, Senior Vice President and Head of the CDMO Business Unit at Apeloa, highlighted the company's commitment to achieving complete resonance with its clients, delivering speed, uncompromised quality, and cost efficiency to accelerate the development and commercial production of life-saving, affordable medicines.

Apeloa's mission of "Technology for Health" is reflected in its end-to-end capabilities across intermediates, APIs, and finished formulations. The company's focus on advanced green chemistry and high-barrier technology platforms has positioned it as a trusted global development partner. With eight advanced technical platforms and a strong regulatory compliance record, Apeloa continues to drive innovation and excellence in the pharmaceutical industry.